Trial Profile
A phase II study of gemcitabine combination with TS-1 [S-1] in patient with advanced or recurred pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; TS 01 (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 Oct 2007 Status changed from recruiting to completed.
- 21 Mar 2007 New trial record.